Physician profile
Paul A Muna Aguon
NPI 1154771673
$26,162.22
in general payments reported to CMS, 2019-2025
11 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $134 · 2022: $13K · 2023: $13K · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $13K · Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $12,500.00 |
| Food and Beverage | $493.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25,140.29 | 2022-2023 | Exalt Model D, Orise |
| Steris Corporation | $216.87 | 2022 | |
| Olympus America INC. | $207.22 | 2025 | Single Use Ligating Device, Disposable Emr Kit, Endoclot Sis |
| Abbvie INC. | $154.30 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $128.28 | 2020-2021 | |
| Conmed Corporation | $95.69 | 2023 | Conmed Biliary |
| Edwards Lifesciences Corporation | $94.59 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Dynavax Technologies Corporation | $19.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.37 | 2022 | |
| Celgene Corporation | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Muna Aguon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.